Special Issue

Amyloid Composition and Structure-Based Development of Therapeutic and Diagnostic Agents

Message from the Guest Editors

The treatment and diagnosis of systemic amyloidosis is a constantly developing and important field. Despite remarkable advances in these areas over the last few vears, there remain significant unmet clinical needs and improvements in clinical care that can be made. especially in the rarer forms of hereditary amyloidosis. This Special Issue, entitled "Amyloid Composition and Structure-Based Development of Therapeutic and Diagnostic Agents", seeks to provide a comprehensive collection of informative articles that describe the interrelationship between an understanding of the structure of amyloid and the development of clinically relevant therapeutics and diagnostics. We cordially invite you to contribute an article to this volume as either original research, a mini review, or a clinical case study. The aim of this Special Issue is to highlight diagnostic and therapeutic reagents that were developed, or may be developed, based on the composition of amyloid and the growing appreciation of the structure of amyloidogenic proteins and amyloid fibrils.

Guest Editors

Dr. Emily B. Martin

Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA

Prof. Dr. Jonathan S. Wall

Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA

Deadline for manuscript submissions

closed (25 May 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/189270

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

